Navigation Links
Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
Date:7/16/2008

tudies has been locked.

About VIAject(TM)

VIAject(TM) is an ultra rapid-acting injectable human insulin intended for meal-time use by patients with Type 1 or Type 2 diabetes. In Phase I and Phase II clinical trials, VIAject(TM) has been shown to have a more rapid onset of activity than those reported for the existing rapid-acting insulin analogs. As a result, VIAject(TM) may be safer, require a lower dose and promote weight loss when compared to currently marketed meal-time insulins. VIAject(TM) has been tested in two pivotal Phase III clinical trials, which compared the effects of VIAject(TM) to Humulin(R) R, the leading recombinant human insulin.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs. The Company's lead product candidate, VIAject(TM), is an ultra rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) has been tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM) a sublingual tablet formulation of insulin in the Phase I stage of clinical testing, and two pre-clinical osteoporosis product candidates. For further information regarding Biodel, please visit the Company's website at http://www.biodel.com.

Safe Harbor

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, including statements regarding our strategy, future operations, future clinical trial results, future financial position, future revenues, projected costs, prospects, plans and objectives
'/>"/>

SOURCE Biodel Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)
2. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
3. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
4. MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion
5. Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
6. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
7. Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients
8. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
9. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
10. Sosei Announces Completion of Phase III Trial for NorLevo(R)
11. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... , NEW YORK, Nov. 25 R...ch report is available in its catalogue: ,, Un...ecasts to 2015 ,, http://www.reportlinker.com...ysis-and-Forecasts-to-2015.html ,, United Stat... 2015 ,, Summary ,, This report is an esse...
(Date:11/25/2009)... , EAST BRUNSWICK, N.J., Nov. 25 /PRNewsw...ufacturer of direct digital Radiography ( ddR ) sy...en acquired by a private Swiss Investor with a lon...ging brand. The acquisition included all assets an...inventory. After 25 years of success and growth Sw...
(Date:11/25/2009)... , CHAPEL HILL, N.C., Nov. 25 /PRNewswir...that Prabhavathi Fernandes, president and chief ex... 21st Annual Health Care Conference at 8:50 a.m. E... in New York City. Dr. Fernandes will provide an ...linical programs for the treatment of drug-resista...
Breaking Medicine Technology:Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 13Swissray International Announces New Ownership 2Americans United for Life Action Says the House Approved Bill to Promote Abortion Overseas is a Grave Injustice 48545 1Scientists advance safety of nanotechnology 48543 1Scientists advance safety of nanotechnology 48543 2Scientists advance safety of nanotechnology 48543 3Favorable Vote From FDA Advisory Committee on SEROQUEL Pediatric Supplemental New Drug Applications 48541 1Favorable Vote From FDA Advisory Committee on SEROQUEL Pediatric Supplemental New Drug Applications 48541 2Favorable Vote From FDA Advisory Committee on SEROQUEL Pediatric Supplemental New Drug Applications 48541 3Favorable Vote From FDA Advisory Committee on SEROQUEL Pediatric Supplemental New Drug Applications 48541 4Favorable Vote From FDA Advisory Committee on SEROQUEL Pediatric Supplemental New Drug Applications 48541 5Favorable Vote From FDA Advisory Committee on SEROQUEL Pediatric Supplemental New Drug Applications 48541 6
...n-free results compared to,sumatriptan, RESEARCH T...,/PRNewswire-FirstCall/ -- -- Findings from two pi... sufferers demonstrated that,Trexima(TM) provided ...rs compared to placebo, and two through 24-hour su...proxen monotherapy. The,results were published tod...
...mmune, a,clinical stage nanomedicine company focus...tifunctional, tumor-targeted therapies has,been se...erican,Society of Clinical Oncology Annual Meeting... will take place from 8:00 am to 12,noon on June 3...sent the poster abstract entitled "Preliminary Res...
Other Medicine Technology:Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data,Published in JAMA 2Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data,Published in JAMA 3Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data,Published in JAMA 4Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data,Published in JAMA 5CytImmune To Present At ASCO Phase I Clinical Trial of CYT-6091 to,be Presented on June 3, 2007 2
(Date:11/27/2009)...NE, France, Nov. 27 Team Garmin-Sl...team dedicated to ethical sporting and developing ...d today that it will become Team Garmin-Transition...w sponsor of the team. Transitions Optical is the ...offering the most advanced photochromic technology...
(Date:11/27/2009)...edented medical, economic burdens, study predicts ...The number of people with diabetes in the United S..., a new study predicts. , That would bring the ...e disease, up from 23.7 million today. , , At th...etes will triple, the study also warns, rising fro...
(Date:11/27/2009)...cialist manufacturers who use medical load cells a...of dollars by bringing in technology partner Flint... of pro-active medical manufacturers are calling i...f their projects, ensuring that progress will not ...entially outdated technology. , ...
(Date:11/26/2009)...umber of Americans living with diabetes will nearl...44.1 million in 2034. Over the same period, spendi...3 billion to $336 billion, even with no increase i...the University of Chicago report in the December i...ith diabetes covered by Medicare will rise from 8....
(Date:11/26/2009)...more letters from the North Pole, Textsanta.net le...from Santa , North Pole, ... efficiencies at the North Pole Santa Claus has ad...ver the globe informed of his Christmas progress a...rch department have identified a large and growing...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2
... DALLAS , May 11 The Beryl Institute recogniz...Star Awards during its recent annual conference. ...ibutions that ultimately make a positive impact on...oration between its vendors. , Meridian Hea...
...edical journals need to be more vigilant, analysis...ws) -- A recent analysis of major medical journals...tween researchers and medical industry companies, ... be published in the June 15 issue of Cancer and...
...ach bit of DNA offers insights to better treatment...thDay News) -- Two major international studies hav...re trove of genes linked to high blood pressure. ,...opher Newton-Cheh, an assistant professor of medic...
... LAS VEGAS and TOWSON, Md., May 11 Founder and pr... Marcia Boyle, traveled to Las Vegas this weekend ...and many other community volunteers, for their eff... ABC,s "Extreme Makeover: Home Edition." The full ...
... PRINCETON, N.J., May 11 Covance Inc. (NYSE: CV...s 2009 Growth Stock Conference on Tuesday, May 12,...ive webcast of the presentation at www.covance.c...sey, is one of the world,s largest and most compre...
...ally exceeds 2,500, officials say, but most cases ...News) -- Confirmed cases of H1N1 swine flu in the...and the U.S. now surpasses Mexico as the country m... weekend, with health officials in Washington stat...
Other Medicine News:Health News:Five Healthcare Organizations Honored as 'Shining Stars' by The Beryl Institute 2Health News:Conflicts of Interest Still Exist in Cancer Research 2Health News:Genes Yield Clues to High Blood Pressure 2Health News:Genes Yield Clues to High Blood Pressure 3Health News:Immune Deficiency Foundation Honors Cerda Family and Volunteers From ABC's 'Extreme Makeover: Home Edition' 2Health News:Immune Deficiency Foundation Honors Cerda Family and Volunteers From ABC's 'Extreme Makeover: Home Edition' 3Health News:U.S. Now Leads World in Swine Flu Cases 2Health News:U.S. Now Leads World in Swine Flu Cases 3Health News:U.S. Now Leads World in Swine Flu Cases 4Health News:U.S. Now Leads World in Swine Flu Cases 5Health News:U.S. Now Leads World in Swine Flu Cases 6Health News:U.S. Now Leads World in Swine Flu Cases 7Health News:U.S. Now Leads World in Swine Flu Cases 8Health News:U.S. Now Leads World in Swine Flu Cases 9Health News:U.S. Now Leads World in Swine Flu Cases 10Health News:U.S. Now Leads World in Swine Flu Cases 11
Reusable Template
MicroTouch LP (Low Profile) Stabilizer
Precision Stepper
SurePoint™ Stepper/Stabilizer EquipmentTable Mount
Medicine Products: